Lipoprotein(a) Internalization in HepG2 Cells is Regulated by Proprotein Convertase Subtilisin Kexin Type 9 Through the Low-Density Lipoprotein Receptor

被引：0
|
作者：
Romagnuolo, Rocco
Seidah, Nabil G.
Koschinsky, Marlys L.
机构：
来源：
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY | 2014年 / 34卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A437
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Evaluation of Proprotein Convertase Subtilisin/Kexin Type 9: Focus on Potential Clinical and Therapeutic Implications for Low-Density Lipoprotein Cholesterol Lowering
    Lose, Jennifer M.
    Dorsch, Michael P.
    Bleske, Barry E.
    PHARMACOTHERAPY, 2013, 33 (04): : 447 - 460
  • [32] Discovery of a New Role of Human Resistin in Hepatocyte Low-Density Lipoprotein Receptor Suppression Mediated in Part by Proprotein Convertase Subtilisin/Kexin Type 9
    Melone, Michelle
    Wilsie, Larissa
    Palyha, Oksana
    Strack, Alison
    Rashid, Shirya
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 59 (19) : 1697 - 1705
  • [33] LIPOPROTEIN(A) AND PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 IN A REPRESENTATIVE SAMPLE OF YOUNG MALES
    Benimetskaya, K.
    Yachmeneva, M.
    Shcherbakova, L.
    Denisova, D.
    Ragino, Y.
    ATHEROSCLEROSIS, 2020, 315 : E146 - E146
  • [34] Lipoprotein(a) reduction with proprotein convertase subtilisin/kexin type 9 inhibitors: An unsolved mystery
    Liberopoulos, Evangelos
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2021, 28 (08) : 813 - 815
  • [35] Update on proprotein convertase subtilisin/kexin type 9 inhibitors, lipoprotein(a) and cardiovascular risk
    Martinez, Laurent O.
    Perret, Bertrand
    Genoux, Annelise
    CURRENT OPINION IN LIPIDOLOGY, 2021, 32 (05) : 324 - 327
  • [36] Effect of proprotein convertase subtilisin/kexin type 9 inhibitors on lipoprotein(a) still to be unravelled
    Sbrana, Francesco
    Dal Pino, Beatrice
    Bigazzi, Federico
    Sampietro, Tiziana
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2019, 26 (07) : 782 - 782
  • [37] The next generation of novel low-density lipoprotein cholesterol-lowering agents: Proprotein convertase subtilisin/kexin 9 inhibitors
    Shen, Li
    Peng, Hongchun
    Xu, Danyan
    Zhao, Shuiping
    PHARMACOLOGICAL RESEARCH, 2013, 73 : 27 - 34
  • [38] Acute effect of proprotein convertase subtilisin/kexin type 9 inhibitor on oxidized low-density lipoprotein and lipid profile in patients at cardiovascular risk
    Li, Yiming
    Sun, Minni
    Li, Ran
    Dou, Min
    Dong, Haozhe
    Xue, Liqi
    Sun, Guoju
    JOURNAL OF CLINICAL BIOCHEMISTRY AND NUTRITION, 2023, 73 (03) : 249 - 254
  • [39] β-Estradiol results in a proprotein convertase subtilisin/kexin type 9-dependent increase in low-density lipoprotein receptor levels in human hepatic HuH7 cells
    Starr, Amanda E.
    Lemieux, Valerie
    Noad, Jenny
    Moore, Jasmine I.
    Dewpura, Thilina
    Raymond, Angela
    Chretien, Michel
    Figeys, Daniel
    Mayne, Janice
    FEBS JOURNAL, 2015, 282 (14) : 2682 - 2696
  • [40] Oxidized Low-Density-Lipoprotein effects in cardiomyocytes require proprotein convertase subtilisin/kexin type 9 (PCSK9)
    Wolf, A.
    Schreckenberg, R.
    Weber, M.
    Schulz, R.
    Schluter, K. -D.
    ACTA PHYSIOLOGICA, 2017, 219 : 135 - 135
12345